Fineline Cube

Follow:
14455 Articles
CompanyDrug

Sino Biopharmaceutical’s Saitanxin Shows 32.4% Response Rate in CDK4/6 Inhibitor-Resistant Breast Cancer at ASCO 2026

HemaCell Therapeutics Secures $44 Million Series B to Advance World's First Megakaryocyte Injection for Platelet Regeneration
CompanyDeals

HemaCell Therapeutics Secures $44 Million Series B to Advance World’s First Megakaryocyte Injection for Platelet Regeneration

Haisco Pharmaceutical Secures FDA Approval for Cypsedo as First Chinese-Developed Intravenous Anesthetic in US Market
CompanyDrug

Haisco Pharmaceutical Secures FDA Approval for Cypsedo as First Chinese-Developed Intravenous Anesthetic in US Market

Shionogi's XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA
CompanyDrug

Shionogi’s XOCOVA Becomes First Oral COVID-19 Post-Exposure Prophylaxis Approved by FDA

BMS' Camzyos Receives FDA Priority Review for Adolescent Obstructive HCM Treatment
CompanyDrug

BMS’ Camzyos Receives FDA Priority Review for Adolescent Obstructive HCM Treatment

CompanyDrug

Livzon Pharmaceutical Secures NMPA Approval for LZM012/XKH004, China’s First IL-17A/F Dual Inhibitor for Ankylosing Spondylitis

CompanyDrug

Changchun High & New Tech Secures FDA Approval for GenSci145, Mutation-Selective PI3Kα Inhibitor for PIK3CA-Mutant Solid Tumors

CompanyDrug

Changchun High & New Tech Secures FDA Clearance for GenSci136 Clinical Study in Generalized Myasthenia Gravis

CompanyDrug

Legend Biotech Unveils First-in-Human Data for DLL3-Targeted CAR-T Therapy LB2102 in Relapsed Small Cell Lung Cancer at ASCO 2026

CompanyDrug

Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026

Novartis' Scemblix Demonstrates Sustained Superiority Over Standard TKIs in Chronic Myeloid Leukemia with 144-Week ASC4FIRST Data
CompanyDrug

Novartis’ Scemblix Demonstrates Sustained Superiority Over Standard TKIs in Chronic Myeloid Leukemia with 144-Week ASC4FIRST Data

CompanyDeals

Haisco Pharmaceutical and Eli Lilly Forge $3 Billion Drug Discovery Alliance Spanning Multiple Therapeutic Areas